Tyler Van Buren
Stock Analyst at TD Cowen
(1.63)
# 3,364
Out of 4,967 analysts
56
Total ratings
40%
Success rate
-4.19%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Initiates: Buy | n/a | $25.48 | - | 1 | Jul 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | n/a | $27.46 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $15.72 | - | 2 | Dec 12, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $15.89 | +371.99% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $11.87 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $15.95 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $24.19 | +148.04% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $3.09 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $9.84 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $577.90 | +107.65% | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $16.65 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $24.63 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $85 | $112.71 | -24.59% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $52.66 | -43.03% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $16.63 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $69.76 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $37.86 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $18.15 | +65.29% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $50.00 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.03 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $32.24 | +117.12% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.72 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.90 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.53 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $0.24 | +20,838.02% | 1 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $13.68 | +1,544.74% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $10.62 | +8,139.17% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $9.11 | +339.08% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $13.84 | +116.76% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.29 | +20,273.51% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.68 | +2,885.07% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $2.59 | +1,058.30% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $3.04 | +6,478.95% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.29 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $18.75 | - | 1 | Aug 4, 2017 |
IDEAYA Biosciences
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $25.48
Upside: -
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $27.46
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $15.72
Upside: -
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $15.89
Upside: +371.99%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $11.87
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $15.95
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $24.19
Upside: +148.04%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $3.09
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $9.84
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $577.90
Upside: +107.65%
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $16.65
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $24.63
Upside: -
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $112.71
Upside: -24.59%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $52.66
Upside: -43.03%
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $16.63
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $69.76
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $37.86
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $18.15
Upside: +65.29%
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $50.00
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.03
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $32.24
Upside: +117.12%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.72
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.90
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $12.53
Upside: -
Mar 4, 2021
Initiates: Overweight
Price Target: $50
Current: $0.24
Upside: +20,838.02%
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $13.68
Upside: +1,544.74%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $10.62
Upside: +8,139.17%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $9.11
Upside: +339.08%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $13.84
Upside: +116.76%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $0.29
Upside: +20,273.51%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.68
Upside: +2,885.07%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $2.59
Upside: +1,058.30%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $3.04
Upside: +6,478.95%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $4.29
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $18.75
Upside: -